Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Upgraded by Wall Street Zen

Cognition Therapeutics (NASDAQ:CGTX) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other brokerages have also recently weighed in on CGTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cognition Therapeutics in a research report on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of Cognition Therapeutics in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Cognition Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $2.83.

Cognition Therapeutics Stock Performance

Shares of Cognition Therapeutics stock opened at $1.66 on Friday. The stock’s fifty day moving average price is $1.78 and its 200-day moving average price is $1.08. The firm has a market cap of $146.53 million, a P/E ratio of -3.46 and a beta of 1.23. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83.

Cognition Therapeutics (NASDAQ:CGTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Analysts forecast that Cognition Therapeutics will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On Cognition Therapeutics

Institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp purchased a new position in Cognition Therapeutics in the third quarter worth $25,000. Northeast Financial Consultants Inc boosted its position in shares of Cognition Therapeutics by 158.6% in the 1st quarter. Northeast Financial Consultants Inc now owns 63,351 shares of the company’s stock worth $27,000 after purchasing an additional 38,851 shares in the last quarter. CWA Asset Management Group LLC purchased a new position in Cognition Therapeutics during the 3rd quarter worth $34,000. Everhart Financial Group Inc. acquired a new position in Cognition Therapeutics during the 3rd quarter valued at about $43,000. Finally, Bryn Mawr Trust Advisors LLC increased its position in Cognition Therapeutics by 69.1% during the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock valued at $53,000 after buying an additional 16,129 shares in the last quarter. 43.35% of the stock is currently owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.